Crotalus scutulatus venom toxins (CSV toxins)

Crotalus scutulatus venom toxins, primarily associated with the Mojave rattlesnake, constitute a potent mixture of proteins and enzymes that induce severe neurotoxic and hemotoxic effects. The most critical component is Mojave toxin, a heterodimeric phospholipase A2 (PLA2) that inhibits presynaptic neurotransmitter release at the neuromuscular junction, leading to muscle weakness and potential respiratory failure (UniProt P01416, P01417). In addition to neurotoxins, the venom contains various snake venom metalloproteinases (SVMPs) and serine proteases that interfere with the coagulation cascade, causing systemic coagulopathy and localized tissue damage (StatPearls, PMID: 30725902). These toxins are the direct targets of polyvalent antivenoms, which consist of immunoglobulin fragments designed to bind and neutralize the toxins before they can reach their physiological receptors (FDA Label: CroFab). Clinical presentation can vary significantly between 'Type A' populations, which exhibit high neurotoxicity, and 'Type B' populations, which are primarily hemotoxic, necessitating careful diagnostic monitoring (PubMed: 22683416). Treatment efficacy is typically measured by the stabilization of neurological symptoms and the normalization of hematologic parameters like fibrinogen and platelet counts.

Other names

Mojave rattlesnake venom toxinsMojave toxinCrotalus scutulatus toxinsMtx

Antibody-antigen binding and neutralization of circulating venom toxins to prevent further interaction with physiological targets.